Loading...
Market
What will be the stock price of Immuneering at the end of 2024?
3
Resolution / Starting Odds
Below $20 • 25%
$20 to $30 • 25%
$30 to $40 • 25%
Above $40 • 25%
Stock market data from financial platforms like NASDAQ or Bloomberg
Story
Immuneering ($IMRX) Announces Positive Phase 2a Data for Pancreatic Cancer Drug
Sep 14, 2024, 07:02 AM
Immuneering has announced positive initial Phase 2a data for its drug IMM-1-104 in combination with chemotherapy in first-line pancreatic cancer patients. The data includes both complete and partial responses, indicating promising efficacy for the treatment. This development is a significant step forward in the fight against pancreatic cancer. The drug is listed under the ticker $IMRX.
View original story
Similar markets
Below $5 • 25%
$5 - $10 • 25%
$10 - $15 • 25%
Above $15 • 25%
Less than $1 • 25%
$1 to $2 • 25%
$2 to $3 • 25%
More than $3 • 25%
Below $0.50 • 25%
$0.50 - $0.99 • 25%
$1.00 - $1.49 • 25%
$1.50 and above • 25%
Above $25 • 25%
Between $20 and $25 • 25%
Between $15 and $20 • 25%
Below $15 • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Below $5 • 25%
$5 to $7.50 • 25%
$7.51 to $10 • 25%
Above $10 • 25%
Below $2 • 25%
$2 to $5 • 25%
Above $10 • 25%
Below $5 • 25%
$5 to $10 • 25%
$10 to $15 • 25%
Above $15 • 25%
Below $20 • 25%
$20 to $40 • 25%
$40 to $60 • 25%
Above $60 • 25%
Below $30 • 25%
$30-$40 • 25%
$40-$50 • 25%
Above $50 • 25%
Below $50 • 25%
$50 to $75 • 25%
$75 to $100 • 25%
Above $100 • 25%
Below $50 • 25%
$50-$100 • 25%
$100-$150 • 25%
Above $150 • 25%
Below $200 • 25%
$200 to $250 • 25%
$250 to $300 • 25%
Above $300 • 25%
Decrease by more than 10% • 25%
Change between -10% and 10% • 25%
Increase by 10% to 20% • 25%
Increase by more than 20% • 25%